

ÖZGEÇMİŞ VE ESERLER LİSTESİ

ÖZGEÇMİŞ

Adı Soyadı: Muhammet Sedat OFLUOĞLU

Doğum Tarihi: 01. Ocak 1965

Öğrenim Durumu:

Derece	Bölüm/Program	Üniversite	Yıl
Lisans			
Y. Lisans			
Doktora/S.Yeterlik/ Tıpta Uzmanlık	CERRAHPAŞA TIP FAKÜLTESİ	İSTANBUL ÜNİVERSİTESİ	2002

Yüksek Lisans Tez Başlığı (özeti ekte) ve Tez Danışman(lar)ı:

Doktora Tezi/S.Yeterlik Çalışması/Tıpta Uzmanlık Tezi Başlığı (özeti ekte) ve Danışman(lar)ı : Radyosinovektomi Holmiyum-166 Ferrik Hidroksitle elde edilen ilk klinik sonuçlar. Prof Dr Levent Kabasakal, Prof Dr İlhami USLU.

Görevler: Yok

Yönetilen Yüksek Lisans Tezler: Yok

Projelerde Yaptığı Görevler: Yok

İdari Görevler :

- Sağlık Ocağı Sorumlu Hekimi (1992-1994)
- Alman Hastanesi Nükleer Tıp Tanı ve Tedavi Kliniği sorumlu hekimi (2002-2014)
- İtalyan Hastanesi Nükleer Tıp Tanı ve Tedavi Kliniği sorumlu hekimi (2008-2014).
- Vatan Hastanesi (2014-2015).
- YeniYüzyıl Üniv. Tıp Fak. Nükleer Tıp Kliniği Öğretim Üyesi Yrd. Doç. Dr. (2015)
- GOP-Taksim EAH Nükleer Tıp Kliniği İdari Sorumlu Hekimi (2015-2018).
- Aydın Üniv. Medikal Parka Hastanesi-Florya Nükleer Tıp Sorumlu Hekimi (2018)

Bilimsel Kuruluşlara Üyelikler :

- Türkiye Nükleer Tıp Derneği (TNTD),
- Avusturya Nükleer Tıp Derneği (ÖGN),
- Avrupa Nükleer Tıp Derneği (EANM).

Son iki yılda verdiği lisans ve lisansüstü düzeydeki dersler (Açılmışsa, yaz döneminde verilen dersler de tabloya ilave edilecektir): **Yok**

Ödüller: Yok

ESERLER

A. Uluslararası hakemli dergilerde yayımlanan makaleler :

- A1.** Radiation exposure around patients after administration of ¹²³I-Metaiodobenzylguanidine (MIBG). **Sedat Ofluoglu**, J. Preitfellner, T. Traub, C. Novotny, B. Füger, E. Havlik, A. Kurtaran. **Nuklearmedizin** **2002**; 41: 221-3.
- A2.** Radiation Synovectomy with Holmium-166 Ferric Hydroxide - a First Experience. **Sedat Ofluoglu**, E. Schwameis, H. Zehetgruber, E. Havlik, A. Wanivenhaus, I. Schweeger, K. Weiss, H. Sinzinger, C. Pirich. **J Nucl Med.** **2002** Nov;43(11):1489-94.
- A3.** Strahlenexposition in der Umgebung von Patienten nach Gabe eines Radiopharmakons in der nuklearmedizinischen Diagnostik. J. Preitfellner, A. Kurtaran, T. Traub, **Sedat Ofluoglu**, E. Havlik. **Strahlenschutz** **2000**; 8: 13-19.
- A4.** New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, **Ofluoglu S**, Halvadjeva E, Smith-Jones P, Flores J, Li SR, Angelberger P, Havlik E, Andrae F, Raderer M, Kurtaran A, Niederle B, Dudczak R. **Q J Nucl Med.** **2000** Mar;44(1):50-8. Review.
- A5.** An unusual visualization of the gallbladder by somatostatin receptor (SSTR) scintigraphy: usefulness of hepatobiliary imaging for differential diagnosis. Kurtaran A, **Ofluoglu S**, Traub T, Tribl B, Speiser P, Grabenwöger F, Schima W, Dudczak R, Virgolini I. **Am J Gastroenterol.** **2000** May;95(5):1367-8.
- A6.** ¹¹¹In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. T. Traub, V. Petkov, **Sedat Ofluoglu**, E. Havlik, P. Angelberger, F. Andrae, E. Halvadjeva, C. Brunner, W. Schima, A. Kurtaran, R. Dudczak, I. Virgolini. **JNM** **2001**; 42: 1309-1315.
- A7.** Impact of Localization Studies on Feasibility of Minimally Invasive Parathyroidectomy in an Endemic Goiter Region G, Prager, C. Czerny, **Sedat Ofluoglu**, A. Kurtaran, C. Passler, K. Kaczirek, C. Scheuba, B. Niederle. **J Am Coll Surg** **2003**;196:541-548.
- A8.** [Radiation doses deriving from patients treated with (166)Ho-ferric hydroxide] Preitfellner J, Pirich C, John P, **Ofluoglu S**, Sinzinger H, Havlik E. **Nuklearmedizin.** **2003** Dec;42(6):251-4. German.
- A9.** Should lidocaine be avoided for local anesthesia in radiation synovectomy? Schweeger I, Pirich C, **Ofluoglu S**, Sinzinger H. **Q J Nucl Med Mol Imaging.** **2004** Sep;48(3):207-10. PMID: 15499294
- A10.** Bone lesion detection with carrier-added ^{99m}Tc-EDTMP in comparison with ^{99m}Tc-DPD. Fueger BJ, Mitterhauser M, Wadsak W, **Ofluoglu S**, Traub T, Karanikas G, Dudczak R, Pirich C. **Nucl Med Commun.** **2004** Apr;25(4):361-5.
- A11.** ¹³N-ammonia rest/stress PET: folic acid improves global coronary vasoreactivity in coronary artery disease patients with normal or elevated homocysteine levels. Graf S, Nikfardjam M, Khorsand A, **Ofluoglu S**, Nekolla S, Dudczak R, Maurer G, Kletter K, Huber K, Pirich C. **Nuklearmedizin.** **2006**;45(6):248-53. PMID: 17149493
- A12.** Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism. Hofmann A, Nawara C, **Ofluoglu S**, Holzmannhofer J, Strohmer B, Pirich C. **Wien Klin Wochenschr.** **2008**;120(15-16):493-8.
- A13.** Coronary Vasoreactivity in Subjects with Thyroid Autoimmunity and Subclinical Hypothyroidism Before and After Supplementation with Thyroxine. Tatjana Traub-Weidinger, Senta Graf, Mohsen Beheshti, **Sedat Ofluoglu**, Georg Zettinig, Aliasghar Khorsand, Stephan G. Nekolla, Kurt Kletter, Robert Dudczak and Christian Pirich. **The Thyroid** **2012. VOL. 22 (3) :245-251.**

B. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (*Proceedings*) basılan bildiriler :

B1. 111In-DOTA-lanreotide (111In-MAURITIUS) scintigraphy in patients with lung tumors. T. Traub, M. Leimer, A. Kurtaran, **Sedat Ofluoglu**, E. Havlik, P. Angelberger, M. Raderer, J. Flores, C. Brunner, P. Smith-Jones, R. Dudczak, I. Virgolini. **J Nucl Med** **1999**; 40:98.

B2. Human biodistribution, safety and absorbed dose of 99mTc-P1666 vasoactive intestinal peptide (VIP) receptor scintigraphy. I. Virgolini, T. Traub, **Sedat Ofluoglu**, A. Kurtaran, M. Raderer, S.R.Li, M. Beck, M. Leimer, P. Angelberger, E. Havlik, R. Dudczak, J. Lister-James. **J Nucl Med** **1999**; 40:244.

B3. 111In-DOTA-lanreotide (111In-MAURITIUS): a novel tracer for patients with lung tumours. T. Traub, V. Petkov, C. Brunner, A. Kurtaran, **Sedat Ofluoglu**, E. Havlik, M. Leimer, P. Angelberger, M. Raderer, R. Dudczak, I. Virgolini. **EJNM** **1999**; 29: 1036.

B4. Comparative study of 111In-DOTA-lanreotide (LAN), 111In-DTPA-D-Phe-1-octreotide (OCT), 111In-DOTA-Tyr3-octreotide (TOCT) and F-18-PET in neuroendocrine tumor patients. I. Virgolini, A. Kurtaran, P. Smith-Jones, E. Havlik, T. Traub, M. Leimer, **Sedat Ofluoglu**, F. Andreae, M. Raderer, P. Angelberger, A. Becherer, B. Niederle, K. Kletter, W. Schima, R. Dudczak. **EJNM** **1999**; 26: 1156.

B5. 99mTc-P1666 vasoactive intestinal peptide (VIP) receptor scintigraphy: clinical efficacy, biodistribution and safety. I. Virgolini, T. Traub, **Sedat Ofluoglu**, A. Kurtaran, M. Raderer, M. Beck, M. Leimer, P. Angelberger, S. Li, C. Novotny, E. Havlik, R. Dudczak, J. Lister-James. **EJNM** **1999**; 26: 1154.

B6. Comparative 111In-DOTA-lanreotide (LAN) and 111In-DOTA-Tyr3-octreotide (TOCT) scintigraphy: biodistribution and absorbed dose. E. Halvadjeva, P. Angelberger, F. Andreae, T. Traub, **Sedat Ofluoglu**, A. Kurtaran, E. Havlik, R. Dudczak, I. Virgolini. **EJNM** **1999**; 26: 1119.

B7. Experimental radiopeptide therapy (ERT) with 90Y-DOTA-Tyr3-DPHE1-octreotide. T. Traub, F. Andreae, P. Angelberger, **Sedat Ofluoglu**, M. Uffmann, A. Kurtaran, E. Halvadjeva, C. Novotny, R. Dudczak, I. Virgolini. **J Nucl Med** **2000**; 41: 14.

B8. Experimental 90Y-DOTA-Tyr3-DPHE1-octreotide therapy in patients with metastatic tumor disease. T. Traub, F. Andreae, P. Angelberger, M. Raderer, **Sedat Ofluoglu**, A. Kurtaran, E. Halvadjeva, R. Dudczak, I. Virgolini. **EJNM** **2000**, A 7012.

B9. „Syndrom X-Mechanismen der reduzierten koronaren Flußreserve“ Graf S, Khorsand A, Gwechenberger M, **Sedat Ofluoglu**, Leitha Th, Kletter K, Pirich Ch, Schmaljohann J, Porenta G, Zehetgruber M Als Vortrag angenommen an der Jahrestagung der Österreichischen Gesellschaft für Nuklearmedizin, 4. Kongress, Februar 2001, Wien **Nuklearmedizin** **2001**;40:A7.

B10. „Prädiktive Parameter für eine reduzierte koronare Flußreserve bei Patienten mit Angina Pectoris und blanden Koronarien“ Graf S, Khorsand A, Gwechenberger M, **Sedat Ofluoglu**, Leitha Th, Pirich Ch, Schmaljohann J, Sochor H, Porenta G, Zehetgruber M Als Vortrag angenommen an der Jahrestagung der Österreichischen Gesellschaft für Nuklearmedizin, 4. Kongress, Februar 2001, **Wien Nuklearmedizin** **2001**;40:A8.

B11. „Myokardvitalität: NOGA Mapping im Vergleich mit FDG-PET und TI-201 “Graf S, Glogar D, Khorsand A, Göngösy M, Pirich Ch, **Sedat Ofluoglu**, Leitha Th, Schmaljohann J, Sochor H, Porenta G Als Vortrag angenommen an der Jahrestagung der Österreichischen Gesellschaft für Nuklearmedizin, 4. Kongress, Februar 2001, Wien **Nuklearmedizin** **2001**;40:A8.

B12. „Mechanisms of a reduced coronary flow reserve in patients with angina and normal angiogram“ Graf S, Khorsand A, Gwechenberger M, **Sedat Ofluoglu**, Pirich Ch, Kletter K, Dudczak R, Sochor H, Porenta G, Zehetgruber M Als Poster angenommen an der Society of Nuclear Medicine, 48th Annual Meeting, **Juni 2001**, Toronto.

- B13.** „Incidence and mechanisms of a reduced coronary flow reserve in patients with angina and normal angiogram“ Graf S, Khorsand A, Gwechenberger M, **Sedat Ofluoglu**, Krcal A, Pirich C, Kletter K, Sochor H, Porenta G, Zehetgruber M Als Vortrag angenommen am XXIII Annual Congress of the European Society of Cardiology, September 2001, Stockholm. Als Best-Abstract der am European Heart eingereichten österreichischen Abstracts Erhalt des „Byk-Reisestipendiums“ der **Österreichischen Kardiologischen Gesellschaft**.
- B14.** Impaired coronary vasoreactivity in subjects with subclinical hypothyroidism as evidenced by N-13-ammonia rest/stress PET. Pirich C, **Sedat Ofluoglu**, Graf S, Zettinig G, Traub T, Dobrocemsky G, Nekolla S, Dudczak R, Kletter K. **J of Nucl Med.** **2002**, Vol 43, Iss 5, pp 183.
- B15.** Impact of dietary supplementation with folic acid on coronary vasoreactivity in subjects with manifested coronary artery disease as assessed by (13) NH (3) rest/stress PET. Pirich C, Nikfardjam M, **Sedat Ofluoglu**, Graf S, Nekolla S, Khorsand A, Dudczak R, Kletter K. **J Nucl Med.** **2002**, Vol 43, Iss 5, pp 184.
- B16.** Incidence and mechanisms of a reduced coronary flow reserve in patients with angina and normal angiogram. Zehetgruber M, Graf S, Khorsand A, Gwechenberger M, **Sedat Ofluoglu**, Pirich C, Porenta G, Sochor H, Krcal A, Kletter K. **European Heart Journal** **2001**, Vol 22, pp 474-474.
- B17.** Carbon-11 acetate PET imaging in prostate cancer patients with rising PSA after radical therapy. Preliminary results. Kurtaran A, Wachter S, Becherer A, **Sedat Ofluoglu**, Schmaljohann J, Djavan B, Dudczak R, Kletter K. **Eur. J. of Nucl. Med.** **2001**, Vol 28, Iss 8, pp OS 292.
- B18.** The Vienna-protocol on repeated low-dose 153Sm-EDTMP therapy induces pain palliation and lesion regression/stabilisation. Sinzinger H, Weiss K, Granegger S, **Sedat Ofluoglu**, Kratzik CH, Hajek CH. **Eur. J. of Nucl. Med.** **2001**, Vol 28, Iss 8, pp PS477.
- B19.** Radiation hazard for patients and relatives after pain palliation with 30 mCi 153Sm-EDTMP Sinzinger H, **Sedat Ofluoglu**, Havlik E, Granegger S. **Eur. J. of Nucl. Med.** **2001**, Vol 28, Iss 8, pp PS483.
- B20.** Radiation synovectomy with Holmium-166 ferric hydroxide – A first experience. **Sedat Ofluoglu**, Schwameis E, Havlik E, Wanivenhaus a, Sinzinger H, Pirich C. **Eur. J. of Nucl. Med.** **2001**, Vol 28, Iss 8, pp PS667.
- B21.** Performing F-18-FDG and C-11-Methionine PET in the follow-up of gliomas after treatment – Are double investigations useful? Asenbaum S, Pirich C, Potzi C, **Sedat Ofluoglu**, Moameni A, Kletter K. **Journal of Nucl. Med.** **2001**, Vol 42, Iss 5, pp 974.
- B22.** Distinction between focal nodular hyperplasia (FHN) and liver metastasis by F-18-FDG PET. Kurtaran A, Becherer A, Mueller C, Raderer M, Schmaljohann J, Schima J, **Sedat Ofluoglu**, Dudczak R, Kletter K, Virgolini I. **Journal of Nucl. Med.** **2000**, Vol 41, Iss 5, pp 1304.
- B23.** Y-90-DOTA-Tyr3-DPHE1-Oktreotid Therapie bei Patienten mit metastasierter Tumorerkrankung. T. Traub, F. Andreae, P. Angelberger, M. Uffmann, P. M. Raderer, **Sedat Ofluoglu**, A. Kurtaran, R. Dudczak, I. Virgolini. **Nuklearmedizin** **1/2001**, V 14.
- B24.** Bestimmung der Biodistribution und der Biokinetik von Radiopharmazeutika in der Therapie mit einem Ganzkörperzähler. H. Fischer, H. Aiginger, S. Granegger, E. Havlik, **S. Ofluoglu**, C. Pirich, H. Sinzinger, F. Steger. **2002**, Leoben.
- B25.** Tc-99m, Tc99m-MIBI, Tl-201-Chlorid, In-111-DTPA-D-Phe-1-Oct ve I-123 MIBG Aplikasyonu sonucu hastanın çevresine yaydığı radyasyon dozu. **S. Ofluoglu**, J. Preitfellner, E. Havlik, L. Kabasakal ve A. Kurtaran. 5th international congress of nuclear oncology. 1-5 mayis **2002**, kusadasi.
- B26.** Lenfödem kliniğimizde Takipli En Küçük Hasta: 21 AYLIK. Evrim Coşkun Çelik, **Sedat Ofluoglu**, Gül Tuğba Bulut, GOP Taksim EAH, Fizik Tedavi ve Rehabilitasyon kliniği, GOP Taksim EAH Nükleer Tıp Kliniği (**2017**, 2. Lenfödem Sempozyumu, Ankara)

C. Yazılan uluslararası kitaplar veya kitaplarda bölümler : YOK.

D. Ulusal hakemli dergilerde yayımlanan makaleler : YOK.

E. Ulusal bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler:

E1. 'Amiodarone ile oluşan tirotoksikoz ve hipotiroidizmin sıklığı ve önceden tahmin edilebilirliği' **Sedat Ofluoglu**, Andrea Hoffman, Johannes Holzmanhofer ve Christian Pirich. 3. Türkiye Tiroid Hastalıkları Kongresi. 18-20 Nisan 2008, Trabzon.

E2. Tanısal amaçlı Nükleer Tıp uygulamalarında hastanın çevresine yaydığı radyasyon dozu. **Sedat Ofluoglu**, J. Preitfellner, B. J. Fueger, T. Traub, C. Novotny, E. Havlik ve A. Kurtaran. 5th international congress of nuclear oncology. 1-5 mayıs 2002, kusalasi.

E3. Tc-99m, Tc99m-MIBI, Tl-201-Chlorid, In-111-DTPA-D-Phe-1-Oct ve I-123 MIBG Aplikasyonu sonucu hastanın çevresine yaydığı radyasyon dozu. **S. Ofluoglu**, J. Preitfellner, E. Havlik, L. Kabasakal ve A. Kurtaran. 5th international congress of nuclear oncology. 1-5 mayıs 2002, kusalasi.

F. Diğer yayınlar : Toplantı Metinleri

F1. A novel and promising tracer for patients with lung tumors: 111In-DOTA-lanreotide (111In-MAURITIUS). T. Traub, P. Petkov, C. Brunner, A. Kurtaran, Sedat Ofluoglu, E. Havlik, M. Leimer, P. Angelberger, M. Raderer, F. Andreae, R. Dudczak, I. Virgolini. 2nd International Wörthersee Symposium in Nuclear Medicine, Velden, Austria, May 13-15, 1999.

F2. Clinical application of 111In-pentetreotide, 111In-DOTA-lanreotide, and 123I-vasoactive intestinal peptide scintigraphy. T. Traub, Sedat Ofluoglu, M. Uffmann, A. Kurtaran, M. Raderer, J. Flores, R. Dudczak, I. Virgolini. International Symposium of Neuroendocrine Oncology, Biology and Clinical Aspects, Torino, Italy, March, 22nd-24th, 1999.